2、本次会议于2023年8月28日以现场结合通讯表决方式在公司会议室召开。 证券代码：300108 证券简称：*ST吉药 公告编号：2023-075 3、本次会议应出席监事3名，实际出席监事3名。 吉药控股集团股份有限公司 4、本次会议由监事会主席任文安先生召集和主持。 第五届监事会第七次会议决议公告 本公司及其监事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、吉药控股集团股份有限公司（以下简称"公司"）第五届监事会第七次 会议（以下简称"本次会议"）通知于2023年8月18日以邮件、电话等形式发出。 特此公告。 本议案 3 票同意，0 票反对，0 票弃权获得通过。 三、备查文件 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等有 关法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 二、监事会会议审议情况 公司第五届监事会第七次会议决议。 经与会监事表决，本次会议形成如下决议： 审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制的《吉药控股集团股份有限公司 2023 年半 ...

2023 年 08 月 28 日 吉药控股集团股份有限公司独立董事 （一）公司控股股东及其他关联方不存在占用公司资金的情况，也不存在以 前年度发生并累计至本报告期内的违规关联方占用资金情况。 关于公司第五届董事会第十次会议相关事项的独立意见 （二）本报告期内，公司不存在为控股股东及其关联方提供担保的情况，公 司未发生对全资、控股子公司、参股公司提供担保以外的担保事项，公司为全资、 控股子公司担保的决策程序符合中国证监会、深圳证券交易所的相关规定，不存 在损害公司和公司股东利益的情形。 作为吉药控股集团股份有限公司（以下简称"公司"）的独立董事，我们依 据《深圳证券交易所创业板股票上市规则》、《关于在上市公司建立独立董事制 度的指导意见》《吉药控股集团股份有限公司章程》（以下简称"《公司章程》"） 等法律法规和规范性文件的有关规定，对公司召开第五届董事会第十次会议审议 的相关事项发表如下独立意见： 特此公告 关于公司控股股东及其他关联方资金占用、公司当期对外担保情况的独立 意见 独立董事：于军、李建华 根据中国证监会《关于规范上市公司与关联方资金往来及上市公司对外担保 若干问题的通知》（证监发（2003）56 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2023-073 吉药控股集团股份有限公司 关于公司诉讼进展的公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 吉药控股集团股份有限公司（以下简称"公司"或"吉药控股"）于近日收 到辽宁省大连市中级人民法院《执行通知书》案号：（2023）辽 02 执 1002 号， 现将具体情况说明如下： 申请执行人哈尔滨银行股份有限公司大连分行与你公司金融借款合同纠纷 一案，辽宁省大连市中级人民法院于2023年04月28日作出的（2022）辽02民初692 号民事判决书，已发生法律效力。本院于2023年07月24日依法立案执行。依照《中 华人民共和国民事诉讼法》第二百四十七条、第二百六十条的规定，现令你公司 于接到本通知后立即履行法律文书所确定的义务，并承担迟延履行期间的债务利 息及申请执行费。逾期不履行，本院将依法强制执行。 二、累计诉讼情况 1、与国药控股（中国）融资租赁有限公司（以下简称"国药控股"）借款 纠纷 因国药控股认为金宝药业已构成违约，其对借款人金宝药业及借款担保人吉 药控股、公司子公司江西双龙 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2023-072 吉药控股集团股份有限公司 关于公司控股股东涉及诉讼的进展公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 吉药控股集团股份有限公司（以下简称"公司"或"吉药控股"）近日接到 公司控股股东卢忠奎先生的通知，吉林省梅河口市人民法院根据公司控股股东卢 忠奎先生与原控股股东吉林省本草汇医药科技有限公司（以下简称"本草汇医药"） 之间的股权转让纠纷案出具了《结案通知书》案号：（2023）吉 0581 执恢 98 号文件。现将具体情况公告如下： 一、关于诉讼的基本情况 2021年12月，公司董事卢忠奎先生向梅河口市人民法院就与本草汇医药股权 转让纠纷一案提起诉讼。公司原控股股东本草汇医药收到梅河口市人民法院出具 的《传票》案号：（2021）吉0581民初3847号及《民事起诉状》等文件。 公司于 2022年1月17日在巨潮资讯网（www.cninfo.com.cn）披露了《关于 对深圳证券交易所〈关注函〉的回复公告》（公告编号：2022-018），对上述相 关事项的情况进行了说明。 公司于2 ...

为进一步加强与投资者的互动交流，吉药控股集团股份有限公司（以下简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"2023 年吉林辖区上市公司网上集体业绩说明会"，现将有关事项 公告如下： 证券代码：300108 证券简称：*ST 吉药 公告编号：2023-053 吉药控股集团股份有限公司 关于参加 2023 年吉林辖区上市公司 网上集体业绩说明会的公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 2023 年 5 月 16 日 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景网"投资者关系互动平台"（http://ir.p5w.net）参与 公司业绩说明会,时间为 2023 年 5 月 22 日（星期一）14:00 至 16:00。 届时公司董事长、总经理、董事会秘书卢正法先生，财务总监张忠伟先生将 通过网络在线问答互动的形式，与投资者就 2022 年经营业绩等投资者关注的问 题进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 投资者可于 2023 年 5 月 1 ...

Financial Performance - The company's revenue for Q1 2023 was ¥71,621,163.94, a decrease of 39.31% compared to ¥118,015,687.61 in the same period last year[5] - The net loss attributable to shareholders was ¥20,231,788.56, an improvement of 61.20% from a loss of ¥52,149,950.90 in the previous year[5] - The net loss for the quarter was ¥30,964,687.78, an improvement of 40.7% compared to a net loss of ¥52,275,394.38 in the same period last year[17] - The company's basic and diluted earnings per share were both -¥0.0304, showing a 61.17% improvement from -¥0.0783 in the same period last year[5] - The company reported a gross profit margin of approximately -77.5% for the quarter, indicating significant operational challenges[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,914,375.11, a decline of 277.39% compared to a positive cash flow of ¥3,897,872.36 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥6,914,375.11, contrasting with a net inflow of ¥3,897,872.36 in the previous year[18] - Cash and cash equivalents decreased significantly from CNY 29,955,789.96 to CNY 16,720,883.29, a drop of about 44%[13] - Cash and cash equivalents at the end of the period were ¥11,732,220.95, compared to ¥5,998,060.27 at the end of the previous period, reflecting an increase of 95.5%[20] - The company experienced a net cash outflow from financing activities of ¥4,410,387.77, compared to a larger outflow of ¥11,848,594.83 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,134,579,534.76, down 3.95% from ¥2,222,263,244.50 at the end of the previous year[5] - The total current assets decreased from CNY 540,104,453.27 at the beginning of the year to CNY 517,875,364.26 at the end of the period, representing a decline of approximately 4.3%[13] - Total liabilities decreased from CNY 2,588,572,723.56 to CNY 2,519,558,065.17, reflecting a decline of about 2.7%[14] - The total non-current assets decreased from CNY 1,682,158,791.23 to CNY 1,616,704,170.50, a decline of approximately 3.9%[14] Equity and Retained Earnings - The total equity attributable to shareholders decreased by 26.32% to ¥56,627,299.35 compared to the previous year-end[5] - The total equity attributable to shareholders of the parent company decreased from CNY 76,859,087.91 to CNY 56,627,299.35, a decline of about 26.3%[15] - The company reported a net loss in retained earnings, increasing from CNY -2,226,915,121.89 to CNY -2,247,146,910.45[15] Operational Performance - The company reported a significant decrease in sales revenue due to a decline in domestic and export volumes of downstream products in the chemical sector[8] - Total operating costs amounted to ¥127,061,747.57, down 22.5% from ¥163,961,790.14 year-over-year[16] - Research and development expenses were ¥2,099,855.68, down 33.9% from ¥3,174,932.13 in the previous year[16] - The company incurred financial expenses of ¥37,287,430.41, slightly down from ¥37,711,830.27 year-over-year[16] Government Support - The company received government subsidies amounting to ¥38,440.44, which are closely related to its normal business operations[6]

Financial Performance - The company's operating revenue for 2022 was ¥488,941,568.47, a decrease of 28.60% compared to ¥684,752,355.71 in 2021[19] - The net profit attributable to shareholders of the listed company was a loss of ¥275,737,540.11, an improvement of 38.90% from a loss of ¥451,317,877.99 in the previous year[19] - The cash flow from operating activities showed a net outflow of ¥33,949,889.37, a significant decline from a positive cash flow of ¥33,159,137.37 in 2021[19] - The total assets at the end of 2022 were ¥2,222,263,244.50, down 7.97% from ¥2,414,668,261.93 at the end of 2021[19] - The company's net assets attributable to shareholders improved to ¥76,859,087.91 from a negative net asset of ¥423,603,104.69 in 2021, marking an increase of 118.14%[19] - The basic earnings per share for 2022 were -¥0.4140, an improvement of 38.90% from -¥0.6776 in 2021[19] - The company reported a total revenue of ¥488,941,568.47 for the reporting period, a decrease of 28.60% compared to the previous year[41] - The pharmaceutical sector contributed ¥311,314,402.91, accounting for 63.67% of total revenue, with a year-on-year decline of 34.19%[42] - The chemical sector generated ¥177,627,165.56, representing 36.33% of total revenue, with a decrease of 16.09% compared to the previous year[42] - The gross margin for the pharmaceutical sector was 37.22%, down 9.46% from the previous year[43] - The company reported a total revenue of 1,129.35 million, with a net profit of 291.22 million, reflecting a profit margin of approximately 25.8%[69] - The company reported a total revenue of 1,675 million in 2022, a decrease of 12.26% compared to the previous year[84] - The company experienced a significant drop in net profit, reporting 448 million, which is a decline of 4.48% year-over-year[84] Operational Challenges - The company faced severe liquidity issues, leading to overdue loans and lawsuits, which significantly impacted operations[4] - The company experienced a significant decline in sales and production volumes due to liquidity issues, impacting overall performance[46] - The company did not win any bids in the national or provincial centralized procurement during the reporting period[39] - The company has ongoing litigation with multiple banks, including a case involving a loan dispute with a total amount of 11,381.71 million[136] - The company is currently involved in several legal disputes that remain unresolved, which may affect its operational focus[136] - The company has been recognized for its compliance issues, with allegations of breach of contract related to its financial dealings[136] - The company is actively managing its legal risks associated with its financial agreements, which could influence future financial performance[136] - The company is facing a loan dispute with Industrial Bank, involving an amount of ¥259.91 million, which is still in the process of resolution[135] Research and Development - The company is currently developing one new drug, which is in the stability testing phase, indicating ongoing investment in R&D[34] - The company is focusing on R&D in silicone materials and fine chemicals, aiming to enhance its product offerings and technological capabilities[70] - R&D expenses increased by 8.21% to ¥17,997,376.97, representing 3.68% of total revenue, up from 1.64% in the previous year[55] - The company is in the pilot stage for several R&D projects aimed at developing new products and improving existing processes, which are expected to enhance product quality and economic benefits[53] Governance and Compliance - The company has a total of 5 board members, including 2 independent directors, ensuring compliance with governance standards[77] - The governance structure complies with relevant laws and regulations, ensuring fair treatment of all shareholders, especially minority investors[76] - The company adheres to strict information disclosure practices, ensuring transparency and timely communication with investors[78] - The company’s internal control evaluation report was disclosed on April 28, 2023, ensuring transparency in its internal control processes[118] - The company has established a complete internal control implementation system, with the management responsible for daily operations and the supervisory board overseeing the implementation[111] Strategic Initiatives - The company aims to enhance its logistics and supply chain services to improve efficiency and customer satisfaction[71] - The company is exploring strategic acquisitions to bolster its market position and expand its operational capabilities[70] - The company aims to develop a comprehensive pharmaceutical strategy, focusing on biopharmaceuticals and OTC market sales, while expanding its retail and terminal sales channels[72] - The company is committed to talent development and enhancing its management structure to support its growth strategy[72] Legal and Financial Issues - The company has received a civil judgment regarding a loan dispute with Zhongmin Investment, amounting to ¥45.12 million, which is still ongoing[135] - The company is involved in a loan dispute with China National Pharmaceutical Group, with a claim amount of ¥37.48 million, which is currently under mediation[134] - The company has received a civil mediation document from the court regarding a loan dispute with China Everbright Bank, with a claim amount of 32,402.66 million[137] - The company has received a penalty of 2 million yuan from the China Securities Regulatory Commission for failing to disclose significant litigation matters in a timely manner[142] Employee and Management Structure - The total number of employees at the end of the reporting period was 1,123, with 1,170 employees receiving salaries during the period[105] - The company has 616 production personnel, 151 sales personnel, and 102 technical personnel among its workforce[106] - The total remuneration paid to the board of directors, supervisors, and senior management was CNY 2.5574 million in 2022[92] - The company has a total of 20 individuals in the board and senior management receiving remuneration[92] Future Outlook - The company provided a future outlook projecting a revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[83] - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[82] - The company aims to reduce operational costs by 10% in 2023 through efficiency improvements and technology integration[83]

证券代码：300108 证券简称：*ST 吉药 公告编号：2023-038 吉药控股集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 吉药控股集团股份有限公司（以下简称"公司"）2022 年年度报告已于 2023 年 4 月 28 日刊登在中国证监会指定的创业板信息披露网站上，根据《深圳证券 交易所创业板股票上市规则》、《深圳证券交易所创业板上市公司规范运作指引》 等有关规定，为了让广大投资者进一步了解公司 2022 年年度报告和经营情况， 公司定于 2023 年 5 月 11 日（星期四）下午 15：00-16：00 在全景网举办 2022 年年度业绩网上说明会。本次说明会将采用网络远程方式举行，投资者可登录"全 景•投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长兼董事会秘书卢正法先生，董事 张亮先生，财务总监张忠伟先生，独立董事于军先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投 ...

中准会计师事务所（特殊普通合伙） Zhongzhun Certified Public Accountants 关于对吉药控股集团股份有限公司的关注函的回复 深圳证券交易所创业板公司管理部： 根据贵部下发的关于对吉药控股集团股份有限公司（以下简称"吉药控股" 或"公司"）的关注函（创业板关注函〔2023〕第 39 号）的要求，中准会计师 事务所（特殊普通合伙）（以下简称"本所"）组织相关人员，对贵部关注函中 提及的问题，严格按照要求进行认真、详细的核查，就相关事项回复如下： 问题 2：业绩预告显示，公司收到业绩补偿款、大股东豁免公司债务、子公 司少数股权被司法拍卖等事项预计将累计增加公司净资产 94,559.21 万元；上 述事项未经过会计师事务所审计，能否增厚 2022 年末净资产尚存在重大不确定 性。 请你公司结合上述事项的筹划、决策及执行过程、商业合理性、程序合法合 规性以及是否存在应披露未披露的"抽屉协议"或其他交易安排等，充分说明相 关事项会计处理的确认依据及其合理性，并明确说明公司是否可能因此承担其 他或有债务、上述事项是否存在前提条件或后续安排、上述事项是否与公司正在 筹划的重大事项（如有）为一 ...

根据贵部下发的关于对吉药控股集团股份有限公司（以下简称"吉药控股" 或"公司"）的关注函（创业板关注函〔2023〕第 4 号）的要求，中准会计师 事务所（特殊普通合伙）（以下简称"本所"）组织相关人员，对贵部关注函中 提及的问题，严格按照要求进行认真、详细的核查，就相关事项回复如下： 深圳证券交易所创业板公司管理部： 中准会计师事务所（特殊普通合伙） Zhongzhun Certified Public Accountants 关于对吉药控股集团股份有限公司的关注函的回复 问题 1：公告显示，2022 年 12 月 13 日，朱余勇通过京东网络司法拍卖平 台，以 2,401 万元竞得公司子公司吉林金宝药业股份有限公司（以下简称金宝药 业）48%股权；2022 年 12 月 25 日，吉林股权交易所股份有限公司通化分公司出 具了《股东名册》，朱余勇已完成金宝药业股东的股权变更。前期公司公告显示， 朱余勇系吉林省梅河建设发展有限公司（以下简称梅河建设）的法定代表人，梅 河建设控股股东为梅河口市财政局。 （3）请你公司说明金宝药业股权拍卖事项预计对你公司 2022 年期末净资 产、净利润的影响，相关会计处理的具体依 ...